uniQure N.V.

Uniqure N.V.

Biotechnology • Healthcare • Amsterdam, Netherlands • QURE (NMS)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

31 20 240 6000 Paasheuvelweg 25, Netherlands

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch - Yahoo Finance
Yahoo Finance • Dec 15
uniQure (NASDAQ:QURE) Trading 5.4% Higher - What's Next? - MarketBeat
MarketBeat • Dec 24
QURE INVESTIGATION REMINDER: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
NewMediaWire • Dec 26
UniQure Stock Plummets 52% on Potential FDA Decision. Here’s Why. - Barron's
Barron's • Nov 3
QURE Stock To $500? - Forbes
Forbes • Sep 25

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has uniQure N.V. had layoffs?
No layoff events have been recorded for uniQure N.V. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does uniQure N.V. have?
uniQure N.V. has approximately 209 employees.
What industry is uniQure N.V. in?
uniQure N.V. operates in the Biotechnology industry, within the Healthcare sector.
Is uniQure N.V. a publicly traded company?
Yes, uniQure N.V. is publicly traded under the ticker symbol QURE on the NMS. The company has a market capitalization of approximately $1.55 billion.
Where is uniQure N.V. headquartered?
uniQure N.V. is headquartered in Amsterdam, Netherlands at Paasheuvelweg 25, Netherlands.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.